Difelikefalin acetate is a Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated in chronic kidney disease and pruritus. It is grouped under the following drug class(es): Peptides. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Korsuva and Kapruvia. Its PubChem CID is 91864509.
Difelikefalin acetate
| CAS No | 1024829-44-4 |
|---|---|
| Molecular Formula | C38H57N7O8 |
| Molecular Weight | 739.9 g/mol |
| Synonyms | acetic acid;4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Difelikefalin acetate is a Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated in chronic kidney disease and pruritus.
The listed CAS number is 1024829-44-4.
The listed molecular formula is C38H57N7O8.
The listed molecular weight is 739.9 g/mol.
acetic acid;4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid.
The source lists Korsuva and Kapruvia.